Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort.
Abuabara K, Eichenfield LF, Bissonnette R, Silverberg JI, Bagel J, Guttman-Yassky E, Thaci D, Simpson EL, Harris JE, Krueger J, Myers DE, Gamelli A, Milutinovic M, Parneix A, Crawford JM, Hildebrand JS, Munoz B, Paller AS. Abuabara K, et al. Among authors: bagel j. J Am Acad Dermatol. 2023 Aug;89(2):345-347. doi: 10.1016/j.jaad.2022.08.065. Epub 2022 Dec 13. J Am Acad Dermatol. 2023. PMID: 36521798 No abstract available.
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
Silverberg JI, Simpson EL, Ardeleanu M, Thaçi D, Barbarot S, Bagel J, Chen Z, Eckert L, Chao J, Korotzer A, Rizova E, Rossi AB, Lu Y, Graham NMH, Hultsch T, Pirozzi G, Akinlade B. Silverberg JI, et al. Among authors: bagel j. Br J Dermatol. 2019 Jul;181(1):80-87. doi: 10.1111/bjd.17791. Epub 2019 Apr 11. Br J Dermatol. 2019. PMID: 30791102 Free PMC article. Clinical Trial.
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS, Seyger MMB, Alejandro Magariños G, Bagel J, Pinter A, Cather J, Keller S, Rodriguez Capriles C, Gontijo Lima R, Gallo G, Little CA, Edson-Heredia E, Li L, Xu W, Papp K; IXORA-PEDS study group. Paller AS, et al. Among authors: bagel j. Br J Dermatol. 2020 Aug;183(2):231-241. doi: 10.1111/bjd.19147. Epub 2020 Jun 15. Br J Dermatol. 2020. PMID: 32316070 Free PMC article. Clinical Trial.
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials.
Blauvelt A, Rosmarin D, Bieber T, Simpson EL, Bagel J, Worm M, Deleuran M, Katoh N, Kawashima M, Shumel B, Chen Z, Rossi AB, Hultsch T, Ardeleanu M. Blauvelt A, et al. Among authors: bagel j. Br J Dermatol. 2019 Jul;181(1):196-197. doi: 10.1111/bjd.17703. Epub 2019 Mar 22. Br J Dermatol. 2019. PMID: 30719707 Free PMC article. No abstract available.
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
Blauvelt A, Armstrong AW, Langley RG, Gebauer K, Thaçi D, Bagel J, Guenther LC, Paul C, Randazzo B, Flavin S, Hsu MC, You Y, Reich K. Blauvelt A, et al. Among authors: bagel j. J Dermatolog Treat. 2022 Jun;33(4):2317-2324. doi: 10.1080/09546634.2021.1959504. Epub 2021 Aug 4. J Dermatolog Treat. 2022. PMID: 34348574 Clinical Trial.
The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry.
Merola JF, Perez Chada LM, Siegel M, Bagel J, Evans C, Lockshin B, Mason M, Guo N, McLean RR, Greenberg JD, Van Voorhees AS. Merola JF, et al. Among authors: bagel j. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):2051-2058. doi: 10.1111/jdv.16274. Epub 2020 Jun 9. J Eur Acad Dermatol Venereol. 2020. PMID: 32027420
133 results